Scribe Therapeutics (SCTX) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($400.8 million vs $259.0 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCTX | ZNTL |
|---|---|---|
| Share price | $21.17 | $2.64 |
| Market cap | $400.78M | $259.04M |
| 1-day change | +10.09% | +5.18% |
| YTD return | — | +85.93% |
| 1-year return | — | +53.05% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-3.84 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $6.95 |
| 52-week low | $13.50 | $1.21 |
| Distance from 52-week high | -46.54% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +169.25% | +177.65% |
| Average volume | 357.40K | 1.21M |
| Shares outstanding | 18.93M | 98.12M |
| Employees | 82 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
SCTX vs ZNTL FAQ
Which is bigger, Scribe Therapeutics or Zentalis Pharmaceuticals?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $400.78M compared with $259.04M for Zentalis Pharmaceuticals (ZNTL).
Are Scribe Therapeutics and Zentalis Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Scribe Therapeutics and Biotechnology: Pharmaceutical Preparations for Zentalis Pharmaceuticals.